Posts found in:
Grantees

Synthetic lethality as a therapeutic strategy for diffuse large B-cell lymphoma We propose a new DLBCL treatment using a concept called synthetic lethality. Synthetic lethality happens when changes in two genes cause cells to die, but a change in either gene alone does not. This approach selectively targets DLBCL with specific changes in specific genes, […]

Novel approaches to therapeutic targets for SF3B1 mutated leukemias Many leukemias have mutations in the SF3B1 gene. Its function is to “stitch together” RNA correctly. RNA is akin to a manufacturing blueprint for making proteins. When mutated, SF3B1 makes abnormal RNA and thus abnormal proteins. We are studying how to target these abnormal RNAs and […]

Elucidating the mechanisms of response and resistance to bispecific antibody therapies in indolent B-cell non-Hodgkin lymphomas Bispecific antibodies, which have emerged as a potent treatment for patients with B-cell lymphomas, activate immune-mediated killing of cancer cells. The proposed research will determine the cellular actors that drive initial and sustained responses to this novel class of […]

Deciphering and Targeting Epigenetic Reader Dependencies in Acute Myeloid Leukemia MLL-rearranged acute myeloid leukemia is an aggressive form of leukemia with poor survival outcomes. In our proposal, we focus on a unique, druggable epigenetic reader crucial for the disease’s progression. By further evaluating this reader, our research could unveil new avenues for more targeted treatments […]

Reducing inflammation in MPN’s: molecular mechanisms and testing potential  disease modifying therapies MPNs are a group of chronic, progressive blood cancers that reduce life expectancy and quality of life. MPN patients have limited therapeutic options, all implying risk. In this project, we will study a risk-free, food-based approach to decrease inflammation in MPNs and test […]

Pilot trial of Telehealth Music Therapy for Cognitive Dysfunction in Hematologic Cancer Survivor Lymphoma, leukemia, and myeloma survivors often experience difficulties with attention and memory after receiving cancer therapies. Unfortunately, treatments for cognitive issues are limited. The PRELUDE study is a randomized controlled trial that will test the feasibility and effects of music therapy for […]

The role of inflammation during STAG-2 mutant MDS and AML initiation and progression Although we know that cohesin mutations cause myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML), we currently cannot target these mutations in a specific manner. My project will identify unique vulnerabilities in cohesin-mutant MDS and AML with the goal to develop less […]

Modulating UBA 1 to treat Myelodysplastic Syndrome Myelodysplastic syndrome (MDS) is a common blood cancer which is caused by genetic mutations. Our lab has identified a new genetic driver of MDS, UBA1, and here we propose to study why these mutations cause disease and how to reverse these defects to help patients.

The Epigenetic Mechanism of Vitamin C in Tumor Suppression Low vitamin C (VC) intake is linked to increased lymphoma risk. However, how VC prevents cancers is unclear. We hypothesize that VC protects our epigenome, which affects how our DNA is read, and helps turn on cancer-suppressing genes. We will identify the proteins that partner with […]

Targeting SLAMF7 using Chimeric Antigen Receptor T-cell Therapy and HMGA1 in Myelofibrosis We propose a novel approach to treating myelofibrosis, a fatal blood cancer, using chimeric antigen receptor (CAR) T-cells. We will study the effects of inhibiting fibrosis-inducing cells with CAR T-cells in mouse models with and without HMGA1 insufficiency. Data from this study will […]

Dissecting MYC Influence on mRNA Processing and  Protein Translation During Acute Myeloid Leukemia Initiation Therapeutic options for patients with Acute Myeloid Leukemia (AML) remain limited, and relapse is common. No studies have addressed the cellular and molecular consequences of MYC overexpression and mutations in AML. Through in-vitro and in-vivo experiments in genetically engineered mouse models, […]

Investigating the role of oncogenic dependency in NPM1-mutant  AML The NPM1 gene is mutated in 20-35% of acute myeloid leukemias (AML). However, it is unclear how mutant NPM1 drives leukemia development and whether the imparted cellular changes are reversible. This proposal aims to define the cellular consequences of mutant NPM1 and whether loss/inhibition of NPM1 […]